Has skepticism about nucleic acid therapeutics shaped the competitive landscape for emerging aptamer companies? Karl Thiel reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505–510 (1990).
Gold, L. & Tuerk, C. Nucleic acid ligands. US patent 5670637 (1997).
Krieg, A. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 (1995).
Nolte, A. et al. Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nat. Biotechnol. 14, 1112–1115 (1996).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thiel, K. Oligo oligarchy—the surprisingly small world of aptamers. Nat Biotechnol 22, 649–651 (2004). https://doi.org/10.1038/nbt0604-649
Issue Date:
DOI: https://doi.org/10.1038/nbt0604-649
This article is cited by
-
Aptamer inhibits Mycobacterium tuberculosis (H37Rv) invasion of macrophage
Molecular Biology Reports (2012)
-
Gene therapy progress and prospects: RNA aptamers
Gene Therapy (2007)
-
Non-SELEX: selection of aptamers without intermediate amplification of candidate oligonucleotides
Nature Protocols (2006)
-
Turning aptamers into anticoagulants
Nature Biotechnology (2004)
